TW214546B - - Google Patents
Download PDFInfo
- Publication number
- TW214546B TW214546B TW080102768A TW80102768A TW214546B TW 214546 B TW214546 B TW 214546B TW 080102768 A TW080102768 A TW 080102768A TW 80102768 A TW80102768 A TW 80102768A TW 214546 B TW214546 B TW 214546B
- Authority
- TW
- Taiwan
- Prior art keywords
- phenyl
- bladder
- compound
- active ingredient
- printed
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims abstract description 17
- 206010013990 dysuria Diseases 0.000 claims abstract description 7
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 3
- 239000004480 active ingredient Substances 0.000 claims abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims description 10
- 238000011049 filling Methods 0.000 claims description 7
- 230000027939 micturition Effects 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 1
- 229950001902 dimevamide Drugs 0.000 claims 1
- 238000004898 kneading Methods 0.000 claims 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims 1
- 229960005375 lutein Drugs 0.000 claims 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims 1
- 235000012680 lutein Nutrition 0.000 claims 1
- 239000001656 lutein Substances 0.000 claims 1
- 235000012149 noodles Nutrition 0.000 claims 1
- IPWFJLQDVFKJDU-UHFFFAOYSA-N pentanamide Chemical compound CCCCC(N)=O IPWFJLQDVFKJDU-UHFFFAOYSA-N 0.000 claims 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 7
- 229940124597 therapeutic agent Drugs 0.000 abstract description 6
- 231100000252 nontoxic Toxicity 0.000 abstract description 2
- 230000003000 nontoxic effect Effects 0.000 abstract description 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- -1 polyethylene Polymers 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 230000000694 effects Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 230000008602 contraction Effects 0.000 description 7
- 239000002775 capsule Substances 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000007937 lozenge Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000005392 Spasm Diseases 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000000626 ureter Anatomy 0.000 description 3
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- 208000002881 Colic Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 206010046543 Urinary incontinence Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 230000002079 cooperative effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- DPBLXKKOBLCELK-UHFFFAOYSA-N pentan-1-amine Chemical compound CCCCCN DPBLXKKOBLCELK-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- MVKDNXIKAWKCCS-UHFFFAOYSA-N 3-methyl-1h-pyridin-2-one Chemical compound CC1=CC=CN=C1O MVKDNXIKAWKCCS-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010056948 Automatic bladder Diseases 0.000 description 1
- 206010048994 Bladder spasm Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007027 Calculus urinary Diseases 0.000 description 1
- TWFZGCMQGLPBSX-UHFFFAOYSA-N Carbendazim Natural products C1=CC=C2NC(NC(=O)OC)=NC2=C1 TWFZGCMQGLPBSX-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010063057 Cystitis noninfective Diseases 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 208000005872 Diffuse Esophageal Spasm Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020601 Hyperchlorhydria Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010020853 Hypertonic bladder Diseases 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010030184 Oesophageal spasm Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010046464 Urethral spasm Diseases 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003627 anti-cholesterol Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008993 bowel inflammation Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 239000006013 carbendazim Substances 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 201000003139 chronic cystitis Diseases 0.000 description 1
- 208000013507 chronic prostatitis Diseases 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000009989 contractile response Effects 0.000 description 1
- 230000001595 contractor effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 230000001660 hyperkinetic effect Effects 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- RTWNYYOXLSILQN-UHFFFAOYSA-N methanediamine Chemical compound NCN RTWNYYOXLSILQN-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000003345 natural gas Substances 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 206010029446 nocturia Diseases 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 229940001607 sodium bisulfite Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 229910052716 thallium Inorganic materials 0.000 description 1
- BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- OKBGNVIROKPBTK-UHFFFAOYSA-K thulium(3+);phosphate Chemical compound [Tm+3].[O-]P([O-])([O-])=O OKBGNVIROKPBTK-UHFFFAOYSA-K 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000008281 urolithiasis Diseases 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Description
五、發明説明(1) 條正 補充 A6 B 6 本發明偽關於含有α -苯基-α -啪啶烷酸衍生物或其 鹽之排尿困難治療劑。 本發明目的為提供含有如下式〔I〕所示α-苯基-α 啪啶烷酸衍生物或其鹽之排尿困難治療劑:
CONH 2
.R 2 [I] CT、3 (請先閲讀背面之注意事項再填寫本頁) •裝· 經濟部中央標準局員工消#合作社印製 式中R 1 . R 2及R 3各為低烷基。 於歐洲專利申請公報號碼105458中己知本發明化合物 〔I〕具有抗携港及抗痙攣之活性。因此,可使用本發 明化合物以治療胃濟瘍的痙莩,痛若及/或蟠動過度. 十二指腸潰瘍,罱酸過多,食管痙攣,莆炎,賎炎,刺 激性腸炎症狀,腸绞痛,结雎管炎,胺管炎,幽門痙攀 ,胰腺炎,雎汁分泌困難,逋曩切割術的後患,尿石症 ,卵戴性痛經,多汗症.尿道痙擊等。 然而,未知此化合物可有效治療小便困難,如小便緊 急,尿失禁等=> 下列將對說明窨中所提及各種定義及其較佳例子作更 詳細的說明。 本說明窨中所使用之"低"除非特別説明•一般意指 Cl -6之基,持別是Cl - 4。 Γ •線· 甲 4(2!11X297公货)80. 5. 20,000張(H) 經濟部中央標準局員工消費合作社印製 五、發明説明(2 :; 〆 < 合適的•’低烷基”可為直鐽或分枝,如甲基,乙基,丙 基,異丙基,丁基,第三丁基,戊基,己基等,以甲基 最佳。 化合物〔I〕的適當鹽可為一般無毒性製藥容許鹽, 含有機或無機酸加成發〔如甲酸鹽,乙酸鹽,反丁稀二 酸留,檸檬酸鹽,三氟乙酸發,順丁烯二酸留·酒石酸 鹽,甲磺酸發,苯磺酸盏.甲苯磺酸鹽.鹽酸鹽,氳溴 酸鹽,硫酸發,磷酸铥等〕,等。 須知化合物[I]可因其不對稱破原子而含有1値或1 掴以上立體異構物,且所有的異構物及其混合物皆包含 於本發明範園中。 由下列藥理試驗結果可顯示出使用化合物〔I〕或其 鹽之组成物以治療小便困難的有效性。 試驗化合物 (± )-(2R* )-4-二甲胺基-2 -苯基- 2- (2-¾ 啶基 )戊m胺 試驗1 E之壓力負荷膀胱亢進模式下對膀胱收縮的抑制作 用 〔I〕方法 將重量240-450g雄S.D.鼠以胺甲酸酯(l.〇s/kg)皮下 注射,麻醉。將膀胱於腹部中線切割處暴露且計錄膀胱 内之壓力。即將末端連接有氣球之不銹銷管(外徑1.2Β1Π (請先閲讀背面之注意事項再填寫本頁) •訂· •線. Γ 甲 4 (2j!iX297公¢) 80_ 5. 20,000張(H) 釘45C本气〒β - — --- B6 五、發明説明(3) ,長度5cm)由膀胱圖頂的小切割處插入膀胱,而管子另 一端則連至E力傳動器。將输尿管結紮切割,並將聚乙 烯導管由近端捅入以使尿液流出。 將勝胱充谋水以引發膀胱亢進(迫尿肌反射亢進),將 膀胱中的氣球加以约1 0 πκ H g之水匿。 當膀胱對水壓負荷的收缩反應為穩定時,將試驗化合 物以靜脈投予。 〔I I〕結果 ED3〇 = 0.09 mg/kg 在显之壓力負荷膀肤亢進棋式中膀胱收縮之抑制 100 1- (請先聞面之注再Ϊ表頁) ·—裝· 抑制率(%) 46.6 ±7.6 31.7
n=3 ED^q^ 0.09 mg/kg 訂_ ( 線丨 鳗濟部中央標準局Λ工消费合作社印製 °·01 °·1 I·0 投與置(Bg/kg) 試驗 2 對具有输尿管結紮老E的膀胱排尿反射收縮作用 « 〔 1〕方法 將雄S · D E (齷重2 5 0 - 3 5 (^ )以胺甲酸酯(].0 s / k f; i . P . )麻酔後,於腹之中線切割。於膀胱圓頂切一小段並插 -5- 本紙張尺度適用t«國家標準(CNS)甲4规格(210 X 297公釐〉 214546 M A6 '_^_ _B6_ 五、發明説明(4 ) 入一聚乙烯管後:結紮t於聚乙烯管的另一端連接三路活 栓。將一輸送馬逹連接於其中一値連结點並將傳動器連 至另一艏連結點以測置膀胱内壓力。持績注射生理食鹽 水至膀胱中。當確定達到穩定地排尿反射後,於下次排 尿之前立即將輸尿管结紮且停止注入生理食鹽水。當所 得規律收縮達穩定後,將試驗化合物投予至頸靜脈以估 計其作用。 [I I〕结果 ED5〇 = 0.56 mg / kg 輪尿管结紮老鼠中對排尿反射膀胱收綰之作用 (請先閲讀背面之注意事項再填寫本頁) 丨裝. 抑制率(% 34.7 ±14.1
0. 64.1 ±3.5
.0 ED5 〇= 0.5 6 mg/Jcg 投與量(ag/kg) 訂· .線. «濟部中央標準45R工消费合作社印製 試.驗 3 於分離之天竺m腠胱的抗胺驗檄性效應 〔I〕方法 將龉重400-70CU之雄天竺E以敲駐枕骨部位擊昏並殺 死。以縱向切割製備迫尿肌樣本(15-20ia«長X 5mm厚>, —6— 本紙張尺度通用中國國家標準(CNS)甲4规格(210 X 297名釐) 2i4546 A6 _ .__B6_ 五、發明説明(4A ) 並將其愁浮於含克氏溶液並通以9 5 % Ο 2 - 5 % C 0 2的 M a g π u s水浴中。由張力傳動器記錄等張收縮。以]5分的 間隔變換緩衝溶液5次。平衡時間為1 0分。使用1 0 ^ Μ胺 甲藍膣龄引發收縮,當牧縮逹穩定後,將試驗化合物加 至M a s n u s水浴中並觀察其抗腔鹼激性之效應 [II〕结果
C I C 5〇 = 6 , Ο X 7 ε/ml 對分離天兰鼠勝胱的抗胆鐮榭性反醮 經濟部中央镖準场貝工消费合作社印製
IxlO-7 3.2x10 lxl〇"*6 lxlO*-5 灌度.(S/b1) I裝· 訂- •線_ 試驗 4 急性毒性試.驗 〔I〕方法 以雌雄不拘的老鼠5隻(C r j : C D ( S D丨株)為一群,砍下 法製備試驗化合物的溶液並以靜脈或皮下投予至老鼠 觀察老鼠14天,使用probit法以計算L D =值。 (試驗溶骹的製備) 將試驗化合物溶於H U中,以磺酸氫鈉調整至p Η 6 - 7 , 並以生理食鹽水稀釋至欲得的痪度c -6A- 本紙張尺度遘用中國國家#準(CNS)甲4现格(210 X 297公釐) " " _ 214546 五、發明説明(5 ) A 6 B 6 〔I I ]結果 動物 投予途徑 性別 L D 5〇 ( m ε / k ε ) 老鼠 f C r j : C D ( S D )) 1 . V . 雄性 雌性 47.2 it Ο <Ί ^ Ζ * ό S . C . 雄性 雌性 922 9 15 (請先閱讀背面之注意事項再填寫本頁) •裝·
由上述結果可得知化合物〔I〕具有抗腔驗擻性之活 性且對膀胱收縮具有抑制效用。亦即此化合物可作為排 尿困難,如頻尿,小便緊急,尿失禁等,或是神經性頻 尿神經性勝胱,夜尿症,膀胱不穩定,膀胱痙擊,慢性 膀胱炎,慢性前列腺炎等的治療劑C 由於本發明化合物具有抗膽齡激性活性,預期亦可作 為氣喘,必絞痛等的治療劑。
本發明所使用排尿困難的治療截可以口服,非經_或 外用(局部),以傳統製藥形式,如膠囊,擻膠囊,錠劑 ,粒劑,粉末,錠劑,九劑,軟音,栓劑,注射液,懸 浮液,糖漿等投予至晡乳動物(包含人)C 本發明所使用排便困難之治療劑可借一般步驟,使用 各種傳統製藥用的有機或無機載體而製得,如賦形劑〔 -7 - 甲 4 (21丨1X297公釐)80. 5. 20,000張(H) 訂· .線· 經濟部中央標準局員工消费合作社印製 214546 A 6 B 6 經濟部中央標準局員工消費合作社印製 五、發明説明(6) 如蔗糖,澱粉,甘露糖,山梨糖,乳糖,葡萄糖,纖雒 素,滑石,磷酸鈣,磺酸鈣等],結合劑〔如繼維素, 甲基繼雒素,羥甲基餓維素,聚丙基毗咯烷嗣,明膠* 阿拉伯膠,聚乙二醇,蔗糖,澱粉等〕,崩散劑〔如澱 粉,羧甲基繼雒素,羥丙基澱粉,重磺酸鈉,磷酸鈣, 檸様酸鈣等〕,潤滑劑〔如硬脂酸鎂,a e「〇 s i ],滑石, 十二烷基硫酸鈉等〕,芳香劑〔如摔塚酸,甲醇,甘油 ,桔粉末等〕,防腐劑〔如苯甲酸納,重亞硫酸納,對 羥苯甲酸甲酯,對羥苯甲酸丙酯,等〕,穩定劑〔如, 檸樣酸,檸钹酸納,乙酸等〕,懸浮劑〔如甲基缒維素 ,聚乙烯毗咯烷酮,硬脂酸鋁等〕,分散劑〔如羥丙基 甲基纖雒素等〕,稀釋劑[如水等〕,基劑蠟〔如可可 脂,白色石蠟脂,聚乙二醇等〕 此製藥製劑之活性組成量為可産生欲得療效的最低量 。亦即當以口服或非經腸投予時,每單位劑量為〇 . 2 !D s 至 5 0 0 m g。 此活性組成可以單位劑量0.1ms /病人至500ing /病人 ,一天投予4次。須知上述劑量可依病人年齡及體重。 病情及投予方法而調整。 本發明將由下列製法及例子作更詳盡的說明。 製法 (1)將4 -二甲胺基-2-苯基- 2- (2-¾啶基)戊堪(50.0g) ,水(2 . 7 4 s )及硫酸(5 0 ® 1 )於1 0 0 - 1 0 5 反應2小時。將 (請先閱讀背面之注意事項再填寫本頁) .裝· •訂· *線. 甲 4 (2H1X297公釐)80. 5. 20,000張(H) 經濟部中央標準局員工消費合作社印製 A6 ^- 五、發明説明(7 ) 反應液冷卻,以冰水.(1〇〇®1)稀釋,並倒入二氨甲烷( 4 0 0 B11 )及水(5 0 0 m 1 )中。將水層以2 4 % N a Ο Η調整至ρ Η 1 2 . 5 。收集有機靥,以飽和氣化鈉水洗,並於無水硫酸鎂下 乾燥。加入異丙酵(7 5 m 1 ),丙酮(1 7 5 ία 1 )及濃H C 1 (1 0 . 8 7 g ),並攪拌1 0分。加入種晶(〇 . 〇 5 s )並於2 5 - 3 0 t:下攪拌 1小時後再於-5〜-1 0 t下攪拌1小時。濾集所得結晶, 以二氛甲烷洗並乾燥可得(± )-(2R* ,4R* )-4-二甲胺 基-2-苯基- 2- (2-¾啶基)戊鞺胺鹽酸鹽(26.9g)。 (2)將含(± )_(2R* ,4R* )-4 -二甲胺基-2 -苯基- 2- (2 -啪啶基)戊屘胺鹽酸鹽(2 0 D之水溶掖(8 0 hi 1 )中加入種 晶(0.02g),並於20-25¾及30分内滴加人含NaOH(2.47 g )之水(8 0 si 1 )。於同溫下抿拌]小時。濾集結晶,水洗 並乾燥可得(± ) - ( 2 R * , 4 R * ) - 4 -二甲胺基-2 -苯基-2 -(2-毗啶基)戊醯胺(16 · lg)° 熔點:1 5 6 - 1 5 7 X: 例] 將(±)-(21?*,411米)-4-二甲胺基-2-苯基-2-(2-€啶 基)-戊藍胺(1 2 0 g ),乳糖(1 0 8 0 g )及低取代羥丙基織維素 (11 0 g ) —起混合。滴加入含羥丙基纖維素L ( 2 3 s〗之水( 2 . 4 kg )。配合之後,將混合物乾燥並通以2 0孔的網子以 篩選。於所得粒劑中加入硬脂酸鎂Π 1 g )並混合。將所 得粒劑壓成錠劑(135ms /錠劑)。 甲 4 (2!丨 1X297公釐)80. 5. 20,000張 CH) ^...........................tr...........................線' (請先閱讀背面之注意事項再填寫本頁) 五、發明説明(8 A6 B 6 囊 瞟 得 可 .囊 顧 入 包 劑 粒 得 所 劑 錠 成 壓 未 1 例)o ?將囊 例 膠 (請先閲讀背面之注意事項再场寫本頁) •裝· 訂· •線· 經濟部中央標準局員工消費合作社印製 甲4(21丨丨父297公釐)80.5_ 20,000張(出
Claims (1)
- A7 B7 C7 D7 第80102768號「含有ct-苯基-α-毗啶烷酸衍生物之排 尿困難治療爾」専利案 (82年7月29日烙正) Λ申請専利範圈: 1.—種治療排尿困難的製蕖組成物,内含下式之化合物 或其鹽當作有效成分RJ 式中R1 ,Ra及R3各為低烷基, 配合以製麵容許無*性載鼸或賦形Μ。 2.如申誧専利範園第1項所示製藥组成物,内含(±)_( 2以,41^)-4-二甲胺基-2-苯基-2-(2-毗啶基)戊雄 胺為有效成分。 (請先閲讀背面之注意事項再填宵本頁) •裝· •訂· 經濟部中央揉準局印製 甲 4 (210X297公沒)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10390390 | 1990-04-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW214546B true TW214546B (zh) | 1993-10-11 |
Family
ID=14366388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW080102768A TW214546B (zh) | 1990-04-18 | 1991-04-11 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US5202331A (zh) |
| EP (1) | EP0452809B1 (zh) |
| JP (1) | JP2500821B2 (zh) |
| KR (1) | KR100190823B1 (zh) |
| AT (1) | ATE109003T1 (zh) |
| AU (1) | AU641747B2 (zh) |
| CA (1) | CA2040680A1 (zh) |
| DE (1) | DE69103068T2 (zh) |
| DK (1) | DK0452809T3 (zh) |
| TW (1) | TW214546B (zh) |
| ZA (1) | ZA912589B (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998002432A1 (en) * | 1996-07-16 | 1998-01-22 | Takeda Chemical Industries, Ltd. | Bicyclic compounds for controlling micturition |
| AU2001256714A1 (en) * | 2000-05-15 | 2001-11-26 | Kissei Pharmaceutical Co. Ltd. | Water-based liquid preparation |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5980664A (ja) * | 1982-09-30 | 1984-05-10 | Fujisawa Pharmaceut Co Ltd | α−アリ−ル−α−ピリジル脂肪酸誘導体およびその製法 |
| US4857535A (en) * | 1986-01-09 | 1989-08-15 | United Pharmaceuticals | Anti-spasmodic agents having a heterocyclic ring |
| DE3601196A1 (de) * | 1986-01-17 | 1987-07-23 | Merck Patent Gmbh | 1,4-dihydropyridine |
| US4957941A (en) * | 1987-11-16 | 1990-09-18 | United Pharmaceuticals, Inc. | Anti-spasmdoic agents having an acetylenic bond |
| US5066680A (en) * | 1989-02-14 | 1991-11-19 | Fujisawa Pharmaceutical Co., Ltd. | Novel substituted-acetamide compound and a process for the preparation thereof |
-
1991
- 1991-04-01 US US07/678,244 patent/US5202331A/en not_active Expired - Fee Related
- 1991-04-08 ZA ZA912589A patent/ZA912589B/xx unknown
- 1991-04-10 JP JP3196176A patent/JP2500821B2/ja not_active Expired - Lifetime
- 1991-04-11 AT AT91105753T patent/ATE109003T1/de not_active IP Right Cessation
- 1991-04-11 EP EP91105753A patent/EP0452809B1/en not_active Expired - Lifetime
- 1991-04-11 DK DK91105753.7T patent/DK0452809T3/da active
- 1991-04-11 TW TW080102768A patent/TW214546B/zh active
- 1991-04-11 DE DE69103068T patent/DE69103068T2/de not_active Expired - Fee Related
- 1991-04-16 KR KR1019910006034A patent/KR100190823B1/ko not_active Expired - Fee Related
- 1991-04-16 AU AU75065/91A patent/AU641747B2/en not_active Ceased
- 1991-04-17 CA CA002040680A patent/CA2040680A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ATE109003T1 (de) | 1994-08-15 |
| JPH059118A (ja) | 1993-01-19 |
| ZA912589B (en) | 1992-01-29 |
| DK0452809T3 (da) | 1994-09-05 |
| EP0452809B1 (en) | 1994-07-27 |
| KR100190823B1 (ko) | 1999-06-01 |
| EP0452809A3 (en) | 1992-04-15 |
| DE69103068D1 (de) | 1994-09-01 |
| CA2040680A1 (en) | 1991-10-19 |
| JP2500821B2 (ja) | 1996-05-29 |
| KR910018026A (ko) | 1991-11-30 |
| US5202331A (en) | 1993-04-13 |
| EP0452809A2 (en) | 1991-10-23 |
| AU7506591A (en) | 1991-10-24 |
| AU641747B2 (en) | 1993-09-30 |
| DE69103068T2 (de) | 1995-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI249519B (en) | Immunoregulatory compounds and derivatives and methods of treating diseases therewith | |
| ES2293993T3 (es) | Inhibidores de produccion de tnf-alfa. | |
| TW200806641A (en) | Substituted aromatic compounds for inflammation and immune-related uses | |
| TW200812587A (en) | Benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses | |
| TW201018667A (en) | Compounds for inflammation and immune-related uses | |
| JP2002511836A (ja) | 化合物および方法 | |
| TW470742B (en) | Benzimidazole derivatives, preparation and pharmaceutical compositions thereof | |
| CA2671949C (en) | Helicobacter pylori eradicating agent having inhibitory activity on gastric acid secretion | |
| AU6354300A (en) | Phosphate transport inhibitors | |
| NO321606B1 (no) | Pyrrolderivater og medisinsk sammensetning | |
| WO2001082924A1 (en) | Phosphate transport inhibitors | |
| TW467913B (en) | Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt and its preparation | |
| PT92647B (pt) | Processo para a preparacao de 5-cloro-2-< { (3,4-dimetoxi-2-piridinil)-metil}-sulfinil>-1h-benzimidazol e de composicoes farmaceuticas que o contem | |
| TW490465B (en) | Enterokinetic benzamide, the preparation process and the pharmaceutical compositions thereof | |
| WO2024060911A1 (zh) | 苯并异噻唑化合物及其药物组合物和应用 | |
| AU2001261471A1 (en) | Phosphate transport inhibitors | |
| TW445251B (en) | Substituted indanylidineacetylguanidines, process for their preparation, their use as medicaments or diagnostic and medicaments containing them | |
| JPS588044A (ja) | 11−デオキソグリチルレチン酸水素マレ−ト及びそれを有効成分とする医薬 | |
| JPH0338269B2 (zh) | ||
| US20030216449A1 (en) | Phosphate transport inhibitors | |
| LU82797A1 (fr) | Nouveaux amino-2 benzoyl-3 phenylacetamides et leurs homologues cycliques utiles comme medicaments et compositions therapeutiques et formes pharmaceutiques les contenant | |
| TW408103B (en) | Guanidinomethyl hexane carboxylic acid ester derivatives | |
| TW200418462A (en) | 2'-halo-3'-5'-dialkoxyphen-1'-yl-imino-2-imidazolidine and the use thereof as a drug | |
| JPS5883620A (ja) | 薬剤としての4−フエニル−4−オキソ−2−ブテン酸のある種の誘導体及びそれを含有する組成物 | |
| JPS58135881A (ja) | 置換ベンズイミダゾ−ル類、その製造方法と利用、およびこれを含む医薬 |